Gritstone Oncology

Gritstone Oncology

Gritstone Oncology is a Emeryville, California-based biotechnology company developing neoantigen-specific cancer immunotherapies.

All edits by  Khadidiatou Amirou 

Edits on 12 Jul, 2020
Khadidiatou Amirou
Khadidiatou Amirou approved a suggestion from Golden's AI on 12 Jul, 2020
Edits made to:
Article (+13/-13 characters)
Article

Gritstone Oncology is a biotechnology company that specializes in developing cancer immunotherapies. It was established in 2015 by Andrew Allen and Mark Cobbold. The company is headquartered in Emeryville, California, United States. It also maintains operations in Cambridge, Massachusetts and Pleasanton, California. Gritstone Oncology has been a publicly-listed company since 2018 and previously received funding from investors such as Redmile GroupRedmile Group, Lilly Asia Ventures, and GV.

Khadidiatou Amirou
Khadidiatou Amirou edited on 12 Jul, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Founder
Mark Cobbold
Edits on 12 Jul, 2020
Khadidiatou Amirou
Khadidiatou Amirou approved a suggestion from Golden's AI on 12 Jul, 2020
Edits made to:
Article (+24/-24 characters)
Article

Gritstone Oncology is a biotechnology company that specializes in developing cancer immunotherapies. It was established in 2015 by Andrew Allen and Mark Cobbold. The company is headquartered in Emeryville, California, United States. It also maintains operations in Cambridge, MassachusettsCambridge, Massachusetts and Pleasanton, California. Gritstone Oncology has been a publicly-listed company since 2018 and previously received funding from investors such as Redmile Group, Lilly Asia Ventures, and GV.

Khadidiatou Amirou
Khadidiatou Amirou approved a suggestion from Golden's AI on 12 Jul, 2020
Edits made to:
Article (+22/-22 characters)
Article

Gritstone Oncology is a biotechnology company that specializes in developing cancer immunotherapies. It was established in 2015 by Andrew Allen and Mark Cobbold. The company is headquartered in Emeryville, CaliforniaEmeryville, California, United States. It also maintains operations in Cambridge, Massachusetts and Pleasanton, California. Gritstone Oncology has been a publicly-listed company since 2018 and previously received funding from investors such as Redmile Group, Lilly Asia Ventures, and GV.

Khadidiatou Amirou
Khadidiatou Amirou approved a suggestion from Golden's AI on 12 Jul, 2020
Edits made to:
Article (+12/-12 characters)
Article

Gritstone Oncology is a biotechnology company that specializes in developing cancer immunotherapies. It was established in 2015 by Andrew AllenAndrew Allen and Mark Cobbold. The company is headquartered in Emeryville, California, United States. It also maintains operations in Cambridge, Massachusetts and Pleasanton, California. Gritstone Oncology has been a publicly-listed company since 2018 and previously received funding from investors such as Redmile Group, Lilly Asia Ventures, and GV.

Khadidiatou Amirou
Khadidiatou Amirou approved a suggestion from Golden's AI on 12 Jul, 2020
Edits made to:
Article (+19/-19 characters)
Article

Gritstone Oncology is a biotechnology company that specializes in developing cancer immunotherapies. It was established in 2015 by Andrew Allen and Mark Cobbold. The company is headquartered in Emeryville, California, United States. It also maintains operations in Cambridge, Massachusetts and Pleasanton, California. Gritstone Oncology has been a publicly-listed company since 2018 and previously received funding from investors such as Redmile Group, Lilly Asia VenturesLilly Asia Ventures, and GV.

Edits on 11 Jul, 2020
Khadidiatou Amirou
Khadidiatou Amirou edited on 11 Jul, 2020
Edits made to:
Infobox (+5/--2 properties)
Infobox
Business model
Commerce
Company status
Active
Founded date
2015
Founder
Andrew Allen
Investors
GV
Khadidiatou Amirou
Khadidiatou Amirou edited on 11 Jul, 2020
Edits made to:
Description (+129 characters)
Topic thumbnail

Gritstone Oncology

Gritstone Oncology is a Emeryville, California-based biotechnology company developing neoantigen-specific cancer immunotherapies.

Khadidiatou Amirou
Khadidiatou Amirou edited on 11 Jul, 2020
Edits made to:
Article (+1407 characters)
Article

Gritstone Oncology is a biotechnology company that specializes in developing cancer immunotherapies. It was established in 2015 by Andrew Allen and Mark Cobbold. The company is headquartered in Emeryville, California, United States. It also maintains operations in Cambridge, Massachusetts and Pleasanton, California. Gritstone Oncology has been a publicly-listed company since 2018 and previously received funding from investors such as Redmile Group, Lilly Asia Ventures, and GV.

Product & Service

Gritstone Oncology develops personalized cancer immunotherapies, based on identifying tumor-specific neoantigens in cancer patients. The company developed an artificial intelligence called Gristone EDGE, dedicated to discovering specific neoantigens based on certain tumor mutations as derived from a previously existing database, and matching these neoantigens to the appropriate immunotherapy. Gritstone Oncology expects that through the use of these methods, the company can administer the right immunotherapy to boost the patient's immune system, with the goal of eradicating the tumor.

...

The company offers two types of products based on this approach The first one is a more personalized approach tailored for the patient based on their cancer diagnosis and immune system, while the second, called SLATE, utilizes previously proven immunotherapies on patients exhibiting similar types of tumor neoantigens.

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.